NASDAQ: THARTharimmune Inc Stock
$0.38+0.00 (+0%)
Updated Apr 19, 2024
THAR Price
$0.38
Fair Value Price
N/A
Market Cap
$4.43M
52 Week Low
$0.34
52 Week High
$31.50
P/E
-0.05x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.32M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.2
Operating Cash Flow
-$7M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
THAR Overview
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapies for treatment resistant cancers. Its approach targets ferroptosis, an anti-cancer mechanism resulting in iron-mediated cancer cell death. Hillstream BioPharma was incorporated in 2017 and is based in Bridgewater, NJ.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how THAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THAR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
THAR is good value based on its book value relative to its share price (0.48x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
THAR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more THAR due diligence checks available for Premium users.
Be the first to know about important THAR news, forecast changes, insider trades & much more!
THAR News
Valuation
THAR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
15.81x
Market
40.51x
THAR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
5.74x
THAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
THAR's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
THAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.9M
Liabilities
$1.8M
Debt to equity
0.2
THAR's short-term assets ($10.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THAR's short-term assets ($10.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
$0.0
Financing
$9.7M
THAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THAR vs Biotech Stocks
Tharimmune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.